A 5-Question Quiz on Sarcoma

Article

Do you know the most common site of metastasis in soft-tissue sarcoma? Or which histologies are most sensitive to chemotherapy? Answer these questions and more.

Question 1:

Answer and Question 2 on Next Page »

The correct answer is D. Rhabdomyosarcoma

Question 2:

Answer and Question 3 on Next Page »

The correct answer is B. Preoperative radiotherapy may be associated with better local control and increased risk of acute wound complications

Question 3:

Answer and Question 4 on Next Page »

The correct answer is C. 45 to 55 years

Question 4:

Answer and Question 5 on Next Page »

The correct answer is B. Lymphadenectomy is required given the high likelihood of nodal metastasis

Question 5:

Answer on Next Page »

The correct answer is A. Lung

 

Recent Videos
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
4 experts in this video
4 experts in this video
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content
Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.

How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?

Russ Conroy
October 15th 2025
Article

Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

SAR-bisPSMA is a targeted copper theranostic that can be used for either imaging or therapy, depending on which copper isotope is paired with it.

64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC

Tim Cortese
October 15th 2025
Article

The novel PET imaging agent detected significantly more PSMA-positive prostate cancer lesions vs SOC in patients with low PSA levels.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Pathological analysis showed that neoadjuvant radiotherapy was associated with the downstaging of locally advanced rectal cancer.

Neoadjuvant Radiotherapy Improves OS With Trade-Off in Rectal Cancer

Tim Cortese
October 14th 2025
Article

Neoadjuvant radiotherapy prior to surgery was associated with a 3-year OS rate of 88.5% in patients with locally advanced rectal cancer.

The full indication excludes patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.

Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC

Tim Cortese
October 14th 2025
Article

A median OS of 21.3 months was found in the phase 1/1b trial evaluating ficerafusp alfa plus pembrolizumab in those with metastatic and recurrent HNSCC.